Scholars Central

OtherPublished 22 Jul 2016

Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease

Authors: Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov

Clinical Investigation

Volume 5 · Issue 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Sucroferric oxyhydroxide (Velphoro®; Vifor Fresenius Medical Care Renal Pharma Ltd) is an iron-based phosphate binder approved for the control of serum phosphorus concentrations in chronic kidney disease patients receiving dialysis. Clinical data indicate that sucroferric oxyhydroxide has similar efficacy to sevelamer carbonate in lowering serum phosphorus levels; however, with a substantially lower pill burden with on average three to four pills/day versus eight to nine pills/day of sevelamer carbonate. Sucroferric oxyhydroxide is associated with discolored feces, as expected for oral iron-based compounds. Some patients reported mild and transient diarrhea, mostly at the start of treatment, which did not require any interventions. There is minimal iron absorption, without risk of iron overload. Overall, sucroferric oxyhydroxide is an effective, well-tolerated new treatment for managing hyperphosphatemia in dialysis patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Stuart M Sprague”
  • BylineArticles whose byline prints “Morgan Marcuccilli & Viatcheslav Rakov”